Medicover AB earnings date
Medicover AB (5M0B) Q3 2026 Earnings Report
DE:5M0B Q3 2026 EPS Results
- Actual EPS
- EUR 0.16
- Consensus EPS
- EUR 0.17
- Beat/Miss
- Missed by -EUR 0.01
- One Year Ago EPS
- EUR 0.13
DE:5M0B Q3 2026 Revenue Results
- Actual Revenue
- EUR 575.27M
- Expected Revenue
- EUR 601.81M
- Beat/Miss
- Missed by -EUR 26.54M
- YoY Revenue Growth
- -3.67%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- Before Open
- Conference Call
- Wednesday, November 4, 2026
Medicover AB's next earnings date is estimated for February 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive. Management reported sustained organic growth, seven consecutive quarters of year-on-year margin improvement, stronger profitability, improved leverage, a significant India divestment expected to generate approximately EUR 740 million, and continued expansion in Sports and Wellness and Diagnostics. The company acknowledged several near-term challenges, including German genetics reimbursement reform, softer German Diagnostics activity, slower Romanian membership and hospital performance, FX pressure and temporary revenue effects from site changes and prior pricing decisions. Management repeatedly characterized these issues as manageable or temporary and maintained its targets.
Management expects the India transaction to close sometime in November, or it will close in Q4, with India expected not to be in the numbers from Q1 next year onwards; it stands by the targets that have been set before for now. Full-year CapEx will still be between 6% to 6.5% of revenues, the effective tax rate will be between 26% to 30% for the year, and German genetics reimbursement changes are expected to be managed over the course of the next four quarters. B2B growth should start to come through as the full cycle progresses, membership growth is expected to come back, and the company expects new Sports and Wellness facilities to continue opening in Q4 and beyond.
- Consistent Growth and Seventh Consecutive Quarter of Margin ImprovementManagement described another consistent quarter, with 8% organic growth on continuing operations and year-on-year margin improvement for the seventh consecutive quarter. Total revenue was up 6% on a continuing basis, while the company stated that total revenue including India was up 8% versus Q2 and organic revenue was double digit on that basis.
- Strong EBIT, EBITDA and EPS PerformanceEBIT increased 22% to EUR 49.3 million, representing a 110-basis-point year-on-year margin improvement. EBITDA increased to EUR 70.9 million, with the EBITDA rate up 70 basis points year-on-year, while adjusted EBITDA was up 7.1%. EPS increased to just over EUR 0.16 per share. Management also cited a margin movement from 7.5% to 8.6%.
- India Divestment Expected to Provide EUR 740 MillionMedicover and its local partners agreed to sell 100% of the India business for an enterprise value of EUR 1.2 billion. Medicover's 66.1% shareholding is expected to generate approximately EUR 740 million, with completion expected in Q4, potentially in November. Management said the transaction represents a complete exit from India and that the proceeds will help reshape the business and be focused on core countries.
- Healthcare Services Growth and Margin ExpansionHealthcare Services delivered 8% organic growth, with revenue up 6% and pricing contributing approximately 6.3%. EBITDA and margins improved, with the Healthcare Services EBITDA margin increasing from 19.1% to 19.8%. Management cited strong performance in Sports and Ambulatory in Poland, as well as solid fee-for-service and other services performance.
- Sports and Wellness ExpansionSports and Wellness maintained a strong performance trend. The company opened four new sites in Q2 and 16 sites during the year, plans to accelerate openings in Q4 and beyond, and said Poland still has significant room for expansion relative to Western Europe. Management described the business as financially positive and accretive, with performance that likely develops faster than the core healthcare business.
- Growing Customer and Membership Base in Healthcare ServicesThe company's ongoing relationships with regularly paying customers and loyalty-scheme participants increased to 4.1 million people from 3.6 million. The Healthcare Services membership base was described as strong at 1.5 million, and Poland recorded membership growth during the quarter.
- Diagnostics Delivered Solid Organic GrowthDiagnostic Services produced 8.5% organic growth, split approximately 50-50 between price and volume. Revenue increased 6.3%, tests increased, and fee-for-service revenue continued to strengthen. Management said the stronger fee-for-service mix provides greater pricing control and that revenue by country was up across the business.
- Fee-for-Service and Funded Revenue Mix StrengthenedFee-for-service was the group's major payer and strengthened again during the quarter. Funded revenue increased 5%, while management said the payer mix was becoming stronger and that the business was doing substantial work to improve the funded sector.
- MRD Blood-Test Product LaunchedThe genetics team launched an evidence-based minimal residual disease product consisting of a simple blood test to detect early signs of lung cancer returning. Management said the test does not require tumor tissue, can enable earlier and more frequent monitoring, and has indications of identifying an issue 7.4 months earlier than traditional approaches. The company said the methodology may be transferable to other applications.
- Improved Leverage and Return on Invested CapitalLeverage decreased to 2.7 as EBIT grew and the balance sheet remained broadly stable. Return on invested capital increased to 14% from 13% at the start of the year. Management said the company should be debt free once the India transaction closes.
- Strong Cash Generation and CapEx HeadroomManagement characterized cash generation as strong, supported by profit growth, despite timing effects in Q3. Investment CapEx remained below free cash flow, Q3 CapEx was 5.1% of revenue and was split approximately 50-50 between maintenance and growth, and full-year CapEx guidance remained 6% to 6.5% of revenue.
- Operational Restructuring and New Site PipelineOver the last 12 months, the company closed 118 units while opening 140. Management said the closed units were unprofitable or were being cannibalized after acquisitions, while new sites are intended to build profitability and scale toward targeted return-on-investment metrics.
- Organic Development and Consumer Engagement InitiativesManagement highlighted ongoing organic development, including IT development and consumer-based engagement tools. It also said new products had been introduced or were about to reach the market to stimulate membership growth.
- Strong Position for M&A and Market ConsolidationManagement said the company is well placed to pursue opportunities following the India transaction, supported by a strong fee-for-service and funded payer mix and an expected debt-free balance sheet. It expects further consolidation in its markets and said potential counterparties have approached Medicover since the India deal was announced.
- Romanian Diagnostics Remained a Market LeaderManagement described the Romanian diagnostics business as good and strong, with great growth and a market-leading position. The team plans to repurpose, renavigate, adjust and compensate for the tougher economic environment.
- Targets MaintainedManagement said it stood by the previously set targets for now and maintained full-year effective tax-rate guidance of 26% to 30%.
DE:5M0B Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 10, 2027 | 2026 (Q4) | 0.15- | 0.13 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.170.16 | 0.13 | 25.58% (+0.03) | |
| Jul 22, 2026 | 2026 (Q2) | 0.170.16 | 0.13 | 26.77% (+0.03) | |
| Apr 29, 2026 | 2026 (Q1) | 0.120.15 | 0.13 | 11.28% (+0.01) | |
| Feb 10, 2026 | 2025 (Q4) | 0.120.13 | 0.06 | 124.14% (+0.07) | |
| Nov 05, 2025 | 2025 (Q3) | 0.120.13 | -0.03 | 530.00% (+0.16) | |
| Jul 24, 2025 | 2025 (Q2) | 0.120.13 | 0.04 | 202.38% (+0.09) | |
| Apr 29, 2025 | 2025 (Q1) | 0.090.13 | 0.04 | 224.39% (+0.09) | |
| Feb 12, 2025 | 2024 (Q4) | 0.040.06 | 0.08 | -25.64% (-0.02) | |
| Oct 30, 2024 | 2024 (Q3) | 0.07-0.03 | -0.01 | -328.57% (-0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

